Theranostics in Prostate Cancer Medical Magazine

19 November 2020

Click here for a preview of our medical magazine incorporating previously done cases at MRC: Theranostics in Prostate Cancer Medical Magazine

¹⁷⁷Lutetium-PSMA

Therapeutic radioactive doses for Prostate Cancer 

Peptide-Receptor Radionuclide therapy (PRRT)

General Concept

1. Prostate cancer cells have receptors on their surface called prostate specific membrane antigen (PSMA).
2. We perform diagnostic PET/CT study using ⁶⁸Gallium-PSMA to detect tumors in the body and confirm presence of receptors on tumor cells.
3. We then inject the therapeutic dose (¹⁷⁷Lutetium-PSMA). ¹⁷⁷Lutetium emits short ranged Beta rays of average length of 0.23mm leading to tumor cell damage and at the same time low risk to surrounding healthy cells.

Read More: https://www.misrradiologycenter.com/theranostics/lutetium-psma/